Autopsy report · NCT00278824

Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant Pain

“Difficulty identifying and enrolling eligible patients”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 7 months before it stopped.
• 109 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

ZARS Pharma Inc.

Sponsor type

Industry

Conditions

Pain

Interventions

Matrix Transdermal Fentanyl/CHADD Drug Delivery System; Placebo Patch

Participants

109

Sites

15

Countries

United States

Trials that died the same way

• Continuous Thetaburst Stimulation for the Treatment of Refractory Epilepsy - Safety, Feasibility and Proof-of-concept
  “Difficulty identifying and including eligible patients” (90% match in meaning)
• Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer
  “Difficulty in enrolling patients” (82% match in meaning)
• Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement
  “Unable to enroll appropriate patients” (82% match in meaning)
• Peppermint Oil for Urinary Retention
  “Difficulty enrolling patients” (82% match in meaning)
• Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)
  “difficulty of enrolling patients” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.